Michel Lagueux
Private Equity Investor at Gestion Bio Innovation, Inc.
Profile
Michel Lagueux is currently the President of Gestion Bio Innovation, Inc. He previously held positions such as Chairman, Interim President & CEO at BioSyntech, Inc., President & Chief Executive Officer at Canacure Corp., Director at Akela Pharma, Inc., Director at Verlyx Pharma, Inc., Vice President at Innovatech Montreal, Inc., Senior Vice President-Life Sciences at Fonds de Solidarité FTQ, and Managing Partner at Multiple Capital, Inc.
Michel Lagueux active positions
Companies | Position | Start |
---|---|---|
Gestion Bio Innovation, Inc.
Gestion Bio Innovation, Inc. Investment ManagersFinance Gestion Bio Innovation Inc (Gestion Bio Innovation) is a venture capital subsidiary of Centre Québécois de Valorisation des Biotechnologies founded in 1900. The firm is headquartered in Quebec, Canada. | Private Equity Investor | - |
Former positions of Michel Lagueux
Companies | Position | End |
---|---|---|
Akela Pharma, Inc.
Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Director/Board Member | 2010-02-18 |
BIOSYNTECH, INC. | Chairman | 2009-07-16 |
Fonds de Solidarité FTQ
Fonds de Solidarité FTQ Investment ManagersFinance Fonds de Solidarité FTQ (Fonds Régional de Solidarité FTQ) is a private equity firm founded in June 1983. The firm is headquartered in Montréal, Quebec. | Corporate Officer/Principal | 2008-04-30 |
Innovatech Montreal, Inc.
Innovatech Montreal, Inc. Investment ManagersFinance Innovatech Montréal, Inc. (IMI) is a Montréal-based venture capital company whose shares the Government of Québec holds. | Head-Equity Investments | 2005-06-29 |
Verlyx Pharma, Inc.
Verlyx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Verlyx Pharma, Inc. develops cancer treatments. It is a pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. The firm’s product VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. The company was founded in 1999 by Terry Chow and David Griller and is headquartered in Montréal, Canada. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BIOSYNTECH, INC. | Health Technology |
Private companies | 7 |
---|---|
Innovatech Montreal, Inc.
Innovatech Montreal, Inc. Investment ManagersFinance Innovatech Montréal, Inc. (IMI) is a Montréal-based venture capital company whose shares the Government of Québec holds. | Finance |
Fonds de Solidarité FTQ
Fonds de Solidarité FTQ Investment ManagersFinance Fonds de Solidarité FTQ (Fonds Régional de Solidarité FTQ) is a private equity firm founded in June 1983. The firm is headquartered in Montréal, Quebec. | Finance |
Canacure Corp. | |
Multiple Capital, Inc.
Multiple Capital, Inc. Investment ManagersFinance Founded in 2005, formerly Société Innovatech du Grand Montréal, Multiple Capital is a Montréal-based venture capital subsidiary of Collier Capital Ltd. | Finance |
Akela Pharma, Inc.
Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Health Technology |
Verlyx Pharma, Inc.
Verlyx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Verlyx Pharma, Inc. develops cancer treatments. It is a pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. The firm’s product VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. The company was founded in 1999 by Terry Chow and David Griller and is headquartered in Montréal, Canada. | Health Technology |
Gestion Bio Innovation, Inc.
Gestion Bio Innovation, Inc. Investment ManagersFinance Gestion Bio Innovation Inc (Gestion Bio Innovation) is a venture capital subsidiary of Centre Québécois de Valorisation des Biotechnologies founded in 1900. The firm is headquartered in Quebec, Canada. | Finance |
- Stock Market
- Insiders
- Michel Lagueux